Nektar Tastes Sweet

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

AstraZeneca (NYSE: AZN  ) is drinking nectar, but it might be getting drunk off the stuff. After all, the company gave Nektar Therapeutics (Nasdaq: NKTR  ) one sweet deal yesterday.

Nektar is getting an up-front payment of $125 million and AstraZeneca is taking over development of two compounds. NKTR-118, which has completed phase 2 testing, treats the constipation that's often caused by opioid painkillers. Further back in the pipeline, NKTR-119 combines NKTR-118 with an opioid painkiller, making it more convenient for patients.

In addition to the up-front payment, Nektar could receive as much as $235 million if NKTR-118 reaches milestones like a Food and Drug Administration approval. And it only gets better from there. If approved, Nektar is due tiered sales-milestone payments of as much as $375 million, and double-digit royalties that CEO Howard Robin implied would be a lot higher than 10%.

There are also potential milestone and royalty payments for NKTR-119, although the companies didn't give specifics.

If approved, NKTR-118 would compete with Progenics Pharmaceuticals (Nasdaq: PGNX  ) and Wyeth's (NYSE: WYE  ) Relistor. It would have a distinct advantage of being an oral compound, compared to Relistor, which needs to be injected. Progenics and Wyeth, soon to be Pfizer (NYSE: PFE  ) , are working on an oral version of Relistor, however, so investors may get to see a nice showdown in a few years as both drugs finish phase 3 testing.

The infusion of cash, and not having to pay for the phase 3 trials, is a good move for Nektar. But at a market cap approaching $1 billion, without any late-stage compounds that it hasn't already partnered, Nektar isn't necessarily cheap. Still, management seems to be making sweet deals to keep the company going, and that shouldn't be overlooked.

Motley Fool Rule Breakers is always on the hunt for hot drug stocks and other cutting-edge picks. Click here to see all of our latest discoveries with a free 30-day trial subscription.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Pfizer is a recommendation of the Inside Value newsletter. The Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (4)

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 990108, ~/Articles/ArticleHandler.aspx, 10/24/2016 8:43:10 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 days ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 0.00 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
NKTR $13.34 Down +0.00 +0.00%
Nektar Therapeutic… CAPS Rating: ***
AZN $30.72 Down +0.00 +0.00%
AstraZeneca CAPS Rating: ****
PFE $32.18 Down +0.00 +0.00%
Pfizer CAPS Rating: ****
PGNX $5.54 Down +0.00 +0.00%
Progenics Pharmace… CAPS Rating: ****
WYE.DL $0.00 Down +0.00 +0.00%
Wyeth CAPS Rating: ***